Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.
A new report of zoledronic acid in men with high-risk prostate cancer is the latest in a long line of negative studies that have addressed the prevention of metastasis. We must learn from these studies so that potentially useful agents are not discarded due to poor trial design in the future.
Concerns have been raised regarding the educational value of live surgical events (LSEs) and whether such events compromise patient safety. Now, the European Association of Urology has published a Live Surgery Policy Statement, aimed at protecting patient safety and ensuring that LSEs are conducted in an ethical and accountable manner.
Johnson and Irwig discuss a community of biological males who desire emasculation and commonly resort to self-castration, castration by nonmedical professionals, or self-inflicted testicular damage via injections of toxic substances. Urologists should be aware of the growing popularity of these procedures.
Optimization of the care that paediatric patients with congenital urological anomalies receive as they transition to adult health care could improve clinical outcomes and quality of life. Dan Wood discusses the challenges associated with the provision of lifelong urological care, highlighting the need for development of academic and health systems.
Seminal plasma is a potential source of biomarkers of male reproductive system disorders. Drabovich et al. describe the development of seminal plasma proteomics and the progress towards the clinical use of biomarkers of male infertility and prostate cancer.